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Introduction 
Dyslipidemia is considered as a major risk factor of cardiovascular 
disease (CVD), such as hypertension, diabetes mellitus, myocardial in-
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farction, and stroke.
1-6) Recently, the Third Korea National Health and 
Nutri  tion Examination Survey (KNHANES III, 2005) data showed that 
the prevalence of dyslipidemia has increased from 32.4% in 1998 to 
44.1% in adults.
5) 
Dyslipidemia can be classified into hypercholesterole  mia, hyper-
triglycemia, low high density lipoprotein-cho  lesterol (HDL-C) and 
high low density lipoprotein-cho  lesterol (LDL-C). Dyslipidemia has 
been proven one of major risk factors of CVD in many studies, includ-
ing Framingham Heart Study.
7-9) It is shown that the morbidity and 
mortality of coronary heart disease (CHD) can be decreased by lo-
wering blood cholesterol level. By with the treatment of hypercho-
lesterolemia, CHD mor  tality can be reduced by 20 to 24%.
7)8)10) 
Managing dyslipidemia is known to have a great ef  fect in prevent-
ing the development of CHD and their complications. National Cho-
lesterol Education Program Adult Treatment Panel III (NCEP ATP III) pro-
vided cli  nicians with guidelines in the diagnosis and treatment of high 87 Sun-Ja Choi, et al.
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blood cholesterol. 
The NCEP ATP III guidelines classify patients into CHD risk cate-
gories, based on the presence of CHD, risk equivalents of CHD and mul-
tiple risk factors accord  ing to LDL-C level, to determine their 10-year 
CHD risk distribution.
11) Recently, the Guideline committee of the 
Korean So  ciety of Lipidology and Atherosclerosis published the 
modification of the second edition of its dyslipidemia treatment 
guideline for Koreans.
12) This treatment guideline is somewhat simi-
lar to the NCEP ATP III guideline, although lipid levels in Korean are 
lower than those of western popul  ation. 
In Korea, the prevalence of dyslipidemia has been on the increas-
ing tendency continuously: it is higher in male (54.5%) than female 
(34.0%) across all age groups, and low HDL-  C and hypercholester-
olemia were the dominant subtype of dyslipidemia in Korea.
5)13) The 
KNHANES reported a treatment rate was only 6.8%, and 33.3% of 
patients reached treat  ment target in patients over 20 years of age 
with high LDL-C level (LDL-C ≥160 mg/dL).
5) 
The problem with dyslipidemia control is the ‘treat  ment gap’ ph-
enomenon-meaning failure to adhere to the recommendations 
outlined in established treatment guideline.
14)16)17) Overcoming this 
‘treatment gap’ is a crucial part to prevent CVD and improve its prog-
nosis. For this reason, the United States has already been work  ing to 
decrease the ‘treatment gap’ and to apply treat  ment guideline in cli-
nical practice.
14-17) 
There are many reports on the ‘treatment gap’ in Korea, raising ar-
guments on their representativeness be  cause most studies are car-
ried out in subjects who visit  ed hospitals and clinics.
17-19) This study 
was designed to analyze lipid levels according to CHD risk categories, 
and to investigate awareness and treatment rate of high LDL-C level 
in Korean adults without history of CHD using KNHANES in 2005. 
Subjects and Methods 
Study population 
Our research was based on data obtained in the KN  HANES III, a 
cross-sectional health survey of nationally representative samples 
of Koreans. The KNHANES was conducted in 2005 by the Korea 
Centers for Disease Control and Prevention. The target population 
for this survey was non-institutionalized individuals. The total po-
pulation was 34145 for the purpose of primary sampl  ing. Subjects 
were randomly sampled throughout South Korea, and included in 
the Health Interview Survey. From the total sample population, 
7597 individuals completed the Health Examination Survey. In to-
tal, 5352 individuals aged between the age of 20 and 79 constitut-
ed the study population. Subjects diagnosed with CHD and those 
without measurement of lipid levels were ex  cluded. The final num-
ber of study subjects for the Ko  rean dyslipidemia analysis was 5248 
(2246 male and 3002 female). 
Definition of diseases 
Diabetes mellitus was defined as fasting blood glu  cose level above 
126 mg/dL, and/or treatment with in  sulin or oral antidiabetic medic-
ations, and/or being diagnosed with diabetes mellitus by a doctor. 
Hyper  tension was defined as systolic blood pressure (SBP) over 140 
mm Hg and/or diastolic blood pressure (DBP) over 90 mm Hg, and/
or use of antihypertensive medica  tions and/or diagnosed with hy-
pertension by a doctor. Smoking status was classified as either cur-
rently smok  ing or non-smoking. Current smokers are defined as 
those who smoked more than 100 cigarettes in the past year. Non-
smokers are those who do not smoke currently and those who smok-
ed less than 100 cigarettes in the past year. 
Blood pressure measure and blood analysis 
Blood pressure was measured by trained investigator using stan-
dardized technique. 
Cuff size fitting arm circumference was chosen and the subject 
was sat in a chair a with back rest for 5 mi  nutes to relax before blo-
od pressure was measured three times with a Baumanometer to ob-
tain the average pres  sure. When blood pressure was only measured 
twice, average SBP and DBP from two measurements were used. Blo-
od was collected from the vein following an 8-hour fasting state; 
serum was separated and stored in refri  gerated conditions. Samples 
were transported on the same day to the central institute for anal-
yses within 24 hours. Fasting blood glucose, total cholesterol (TC), 
HDL  -C and triglyceride (TG) were analyzed using a Hitachi 747 au-
to-analyzer (Tokyo, Japan). LDL-C was calculated using the Friedewald 
formula, [LDL-C (mg/dL)=TC (mg/dL)-{HDL-C (mg/dL)+TG (mg/
dL)/5}] for those with TG level below 400 mg/dL.
20) 
High low density lipoprotein-cholesterol level according  
to National Cholesterol Education Program Adult  
Treatment Panel III guidelines 
High LDL-C was classified according to the NCEP ATP III guidelines, 
taking into account the number of major CHD risk factors and Fr-
amingham point score.
11) Age (male over 45, female over 55), hyper-
tension, low HDL-C and current smoking status were defined as 
major CHD risk factors. The target LDL-C level was set according to 
NCEP ATP III.
11) In this study, subjects were divided into two groups 
by target LDL-C: one group in need of therapeutic lifestyle change 
(TLC) and the other in need of drug therapy (Table 1). 
Awareness and treatment rate of high low density 
lipoprotein-cholesterol 
The awareness and treatment rates of high LDL-C were defined 88  Low Density Lipoprotein-Cholesterol Level in Korean Adults
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as follows: awareness rate was investigated by a survey asking for 
disease and diagnosis history among high LDL-C population, in-
cluding previously diagnosed patients and newly diagnosed pati-
ent of dy  slipidemia. Treatment rate was investigated by a survey ask-
ing whether or not they had been taking oral lipid lowering agents. 
Statistical analysis 
All data was analyzed using Statistical Package for the Social Sci-
ences (SPSS) version 12.0 (SPSS, Inc., Chicago, IL, USA) and p<0.05 
was considered statistically signi  ficant. Continuous variables are 
expressed in mean±standard deviation, and discrete variables are ex-
pressed in numbers and proportions. Differences in categori  cal data 
were analyzed using the Chi-square test. 
Results 
General characteristics of the subjects 
The general characteristics of the study population are shown in 
Table 2. The mean age of the subjects for male and female was 46.5 
years and 46.1 years, respectively. Both male and female showed 
the highest distribution in the 40-49 age group (male 26.4%, female 
24.6%). SBP and DBP were higher in male subjects than in female. 
The prevalence of CHD risk factors-hypertension, dia  betes and cur-
rent smoking was significantly higher in male than in female subjects. 
Subject distribution according to lipid levels 
Distribution of lipid levels according to study subjects and age 
groups are shown in Table 3 and Fig. 1. TC level did not significantly 
differ by gender, but LDL-C level was higher in female. Distribution 
of TC and LDL-C levels did not differ significantly by gender. Mean 
HDL-C level was significantly lower in male (42.4 mg/dL) than in fe- 
male (47.3 mg/dL), and those with HDL-C levels lower than 40 mg/
dL were significantly more in male. Mean TG level was significantly 
higher in male than in female, and subjects with higher TG level 
than 200 mg/dL were twice as many in male (22.4%) as in female 
(9.6%) (p<0.001). 
According to lipid levels by age group, high TC (TC ≥240 mg/dL) 
and high LDL-C (LDL-C ≥160 mg/dL) in male increased until 40-49 
years and then decreased after 50 year of age. However, female 
showed continuous increase until 50-59 years of age and then de-
creased. High TG (TG ≥200 mg/dL) in male increas  ed until 40-49 
years and then decreased after 50 years of age. However, female 
increased until 50 years old but the levels stabilized after 50s. Low 
HDL  -C (HDL-C <40 mg/dL) in male didn’t differ signifi  cantly by age 
Table 2. Basic characteristics of the study population by gender in KNHANES III
Variables Total (n=5248) Male (n=2246)  Female (n=3002)  p*
Age (years) 46.3±14.6 46.5±14.1  46.1±14.9 0.276  
20-29  677 (12.9) 274 (12.2)  403 (13.4) 
30-39  1216 (23.2) 497 (22.1)  719 (24.0) 
40-49  1329 (25.3) 592 (26.4)  737 (24.6)  0.001  
50-59  883 (16.8) 396 (17.6)  487 (16.2) 
60-69  759 (14.5) 354 (15.8)  405 (13.5) 
70-79  384 (7.3) 133 (5.9) 251 (8.4)
SBP (mm Hg)  118.7±17.5  122.5±15.8  115.9±18.2  <0.001  
DBP (mm Hg)  77.3±10.8  80.8±10.3  74.7±10.3  <0.001  
CHD risk factors, n (%) 
Hypertension  1350 (25.9)  683 (30.6)  667 (22.3) <0.001  
Diabetes mellitus  437 (8.4) 238 (10.7) 199 (6.7) <0.001
Current smoking 1154 (22.6)  1028 (47.7) 126 (4.3) <0.001
Values are mean±SD or n (%). *Difference between men and women by t-test or Chi-square test. KNHANES III: Third Korea National Health and Nutrition 
Examination Survey, SBP: systolic blood pressure, DBP: diastolic blood pressure, CHD: coronary heart disease
Table 1. LDL-C goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories
11) 
Risk category LDL-C goal (mg/dL) TLC (mg/dL) Consider drug therapy (mg/dL)
CHD risk equivalents (10 year risk >20%) <100  ≥100   100 (<100: consider drug options)  
2+ risk factors (10 year risk ≤20%) <130  ≥130    ≥130 (10 year risk 10-20%, 100-129: consider drug options) 
<130  ≥130 ≥160 (10 year risk <10%)  
0-1 risk factor  <160  ≥160  ≥190 (160-189: LDL-lowering drug optional)  
LDL-C: low density lipoprotein-cholesterol, CHD: coronary heart disease, TLD: therapeutic life style change   89 Sun-Ja Choi, et al.
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groups, but female showed continuous in  crease with age. 
Distribution of subjects who need therapeutic life  style 
change or drug therapy according to different risk 
categories in National Cholesterol Education 
Program Adult Treatment Panel III 
Subject distribution in need of TLC and drug therapy by risk cate-
gories in regard to LDL-C level is shown in Table 4. Among Koreans 
over 20 years old without his  tory of CHD, 9.8% had risks equivalent 
to CHD, 29.5% had more than two risk factors and 60.7% had less 
than two risk factors. Among 483 subjects with CHD-equi  valent 
risks and/or a 10-year CHD risk of >20%, 359 subjects (74.3%) sh-
owed LDL-C levels higher than 100 mg/dL in need of TLC and 74.3% 
was in need of drug therapy with LDL-C levels over 100 mg/dL. Am-
ong 1454 subjects with two or more CHD risk factors and a 10-  year 
CHD risk of ≤20%, 31.0% was in need of TLC with LDL-C levels over 
130 mg/dL, and 18.9% was in need of drug therapy. Among subjects 
with 0-1 CHD risk factors, 5.8% was in need of TLC with LDL-C levels 
higher than 160 mg/dL and 1.0% was in need of drug therapy. Ra-
tio of patients in need of aggres  sive treatment was the highest in 
the group with CHD equivalent risk. 13.5% of the study population 
needed drug treatment. 
Proportion of dyslipidemia by gender 
Subjects with more than one lipid disorder were higher in male 
when the proportion of subjects with combined high LDL-C, high TG 
and low HDL-C was analyzed (Fig. 2). 60.3% of male had ≥1 lipid 
disorder among high LDL-C, high TG and low HDL-C, 23.5% had ≥2 
lipid disorders and 2.8% had all three lipid abnormalities. 39.1% of 
female had ≥1 lipid disorder, 9.7% had ≥2 and 1.2% had all three 
Table 3. Mean value and distribution of lipid levels in KNHANES III
Variables      Total Male Female p*
TC
Mean (mg/dL)   184.7±34.9 185.2±34.8 184.3±35.0 0.397
Distribution 0.378
<200 3641 (69.4) 1546 (68.8) 2095 (69.8)
200-239 1280 (24.4) 567 (25.2) 713 (23.8)
≥240 327 (6.2) 133 (5.9) 194 (6.5)
LDL-C
Mean (mg/dL) 114.0±30.2 113.0±30.4 114.7±30.0 0.043
Distribution 0.749
<100 1732 (33.9) 734 (34.2) 998 (33.6)
100-129 1964 (38.4) 828 (38.6) 1136 (38.3)
130-159 1079 (21.1) 452 (21.1) 627 (21.1)
160-189 272 (5.3) 109 (5.1) 163 (5.5)
≥190 66 (1.3) 23 (1.1) 43 (1.4)
HDL-C
Mean (mg/dL) 45.2±10.9 42.4±10.2 47.3±10.9 <0.001
Distribution <0.001
<40 1762 (33.6) 1013 (45.1) 749 (25.0)
40-59 2956 (56.3) 1094 (48.7) 1862 (62.0)
≥60 530 (10.1) 139 (6.2) 391 (13.0)
TG
Mean (mg/dL) 135.2±121.6 163.5±158.2 114.0±78.1 <0.001
Distribution <0.001
<150 3782 (72.1) 1387 (61.8) 2395 (79.8)
150-199 677 (12.9) 356 (15.9) 321 (10.7)
200-499 715 (13.6) 443 (19.7) 272 (9.1)
≥500 74 (1.4) 60 (2.7) 14 (0.5)
Values are mean±SD or n (%). *Difference between men and women by t-test or Chi-square test. KNHANES III: Third Korea National Health and Nutrition Ex-
amination Survey, TC: total cholesterol, LDL-C: low density lipoprotein-cholesterol, HDL-C: high density lipoprotein-cholesterol, TG: triglyceride 90  Low Density Lipoprotein-Cholesterol Level in Korean Adults
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Fig. 1. The prevalence of TC, LDL-C, HDL-C, and TG levels by age group. TC: total cholesterol, LDL-C: low density lipoprotein-cholesterol, HDL-C: high density 
lipoprotein-cholesterol, TG: triglyceride.
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types of dyslipidemia. 
Awareness and treatment rate of high low density 
lipoprotein-cholesterol 
The awareness and treatment rates of high LDL-C level are shown 
in Table 5. In 984 (19.9%) high LDL  -C subjects, the awareness rate 
was 7.9% (male 7.3%, fe  male 8.5%) and the treatment rate was 
2.1% (male 1.2%, female 3.0%). The awareness and treatment rates 
of high LDL-C level were the highest in the 60-69 age group for 
both genders. The awareness rate in high LDL-  C subjects who requir-
ed drug therapy was 8.1% (male 7.2%, female 9.5%) and the treat-
ment rate was 2.7% (male 1.5%, female 4.4%). The awareness and 
treatment rates in both male and female continuously increased 
from 20-29 to 60-69 years and then decreased from 70-79 years. 
Female showed higher awareness and treatment rates than male. 
When the results were analyzed by NCEP ATP III risk categories in 
regard to LDL-C level, both male and female with 0-1 CHD risk fac-
tor show  ed the lowest awareness and treatment rates. However, the 
awareness and treatment rates were still less than 8% in the group 
with CHD equivalent risks.
Discussion
Recently, cerebrovascular and cardiac diseases were respectively 
the second and third cause of death, there  fore CVD account for 20% 
of overall death in Korea.
21) This study was designed to analyze the 
distribution of dys  lipidemia, the prevalence of high LDL-C level ac-
cording to the NCEP ATP III criteria and to make useful sugges  tions 
that can lead to effective control strategies for high LDL-C level in 
the Korean population using NHANES in 2005. 
The prevalence of hypertension in our study popul  ation was 
25.9%, which was slightly lower than the out  come of 28.5% in a 
study conducted in adults, including CHD patients, over 20 years of 
age in the United States. However, the prevalence of diabetes (8.4% 
vs. 8.8%) and the rates of current smoking (22.6% vs. 23.6%) were 
similar.
22) In our study, the prevalence of major CHD risk factors was 
also higher in male than female across all age group. Male demon-
strated higher prevalence of hypertension (male 30.6%, female 
22.3%), diabetes (male 10.7%, female 6.7%) and current smoking 
rate (male 47.7%, female 4.3%) than female. In addition, among the 
mean lipid levels, TG was higher in male (163.5±158.2 mg/dL) than 
female (114.0±78.1 mg/dL), however, LDL-C (male 113.0±30.4 mg/dL, 
female 114.7±30.0 mg/dL, p=0.043) and HDL-C (male 42.4±10.2 
mg/dL, female 47.3±10.9 mg/dL, p<0.001) were lower in male than 
female. 
Of the study subjects analyzed, 19.9% required TLC and 13.5% 
required drug therapy according to NCEP ATP III. These results were 
lower than that of 28.0% and 25.3% from the United States study 
Table 4. Distribution of LDL-C for therapeutic lifestyle changes (TLC) and drug therapy in different risk categories by NCEP ATP III
Risk category Total TLC Consider drug therapy
CHD risk equivalents (10 year risk >20%)   483 (9.8) 359 (74.3) 359 (74.3)
2+ risk factors (10 year risk ≤20%) 1454 (29.5) 451 (31.0) 222 (15.3) (10 year risk 10-20%)
53 (3.6) (10 year risk <10%)
0-1 risk factor 2997 (60.7) 174 (5.8) 30 (1.0)
Total 4934 984 (19.9) 664 (13.5)
Values are n (%). NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel III, LDL-C: low density lipoprotein-cholesterol, CHD: coronary 
heart disease
9.7 10.8
High LDL-C High LDL-C
Male (60.3%) Female (39.1%)
High TG High TG Low HDL-C Low HDL-C
2.8 1.2
9.3 3.4
1.5 0.9 9.9 4.2
4.9 2.9 22.2 15.6
Fig. 2. Proportion of Korean adults with a combination of high LDL-C, high TG, and low HDL-C. High LDL-C: LDL-C ≥100 mg/dL for patients with coronary hear 
disease (CHD) risk equivalents, ≥130 mg/dL for patients with two or more CHD risk factors, ≥160 mg/dL for those with 0-1 CHD risk factor, High TG: ≥200 mg/
dL, Low HDL-C: <40 mg/dL for men and women. LDL-C: low density lipoprotein-cholesterol, HDL-C: high density lipoprotein-cholesterol, TG: triglyceride.92  Low Density Lipoprotein-Cholesterol Level in Korean Adults
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conducted in adults aged over 20 years, including CHD patients.
22)23) 
In the United States, among subjects in need of TLC and drug therapy 
by risk categories in regard to LDL-C level, there were a lot of sub-
jects in need of TLC and drug therapy in groups with less than two 
CHD risk factors. However, in our study, those who needed TLC and 
drug therapy were highest in subjects with risks equivalent to 
CHD.
22) This outcome indicates a lack of appropriate manage  ment 
of high LDL-C level in the high risk group. In another Korean study 
conducted in patients aged between 20 and 79 who visited the 
health promotion center of me  dical center in 2001, subjects in need 
of TLC and drug therapy were 12.1% and 6.1%, respectively, show-
ing lower prevalence than this study.
24) The reason for this appeared 
to be due to differences in the characteristics of study subjects. Our 
study has shown that subjects with high LDL-C level in need of TLC 
and drug therapy increased by age, and the prevalence of subjects 
in need of TLC and drug therapy were higher in female than in male 
(Table 5). 
Based on ‘Risk assessment chart of a 10-year cardio  cerebro-
vascular disease in Korean’s supplement of dys  lipidemia guideline 
in Korean (2008 February edition)’, the 10-year ischemic heart dis-
ease (IHD) risks were analyzed. No Korean population showed a 
10-year IHD risk of >20%, but 363 subjects (11.6%) exhibited IHD 
eq  uivalent risks, 7 subjects (0.2%) exhibited a 10-year IHD risk of 
10-20% and 42.1% exhibited a 10-year IHD risk of <10%. 1441 sub-
jects (46.0%) had less than two risk factors. 
Risk estimation scoring system for the Korean population includes 
SBP, TC, age and current smoking. Except for HDL-C, these are iden-
tical to the risk factors outlined in Framingham risk score. However, 
SBP and TC range were different (range in Kor  eans: SBP 100-199 mm 
Hg, TC 160-279 mg/dL are de  fined) and age range was also different 
from Framingham risk score, which encompassed ages between 
20-79 versus the Kor  ean scoring system, which encompassed ages 
be  tween 40-70. However, the risk estimation scoring system sug-
gested by the Korean Society of Lipidology and  Atherosclerosis sh-
ould be validated and needs an agreement.
In our study, the proportion of dyslipidemia with combined high 
LDL-C, high TG and low HDL-C le  vels in all age groups was compar-
ed with that of adults in the United States and France: proportion of 
high LDL-C group was relatively low, and proportion of low HDL-C 
and proportion of high TG were relatively high. Apart from these re-
sults, lipid disorder comprised of low HDL-C and high TG showed 
high proportion.
23)25) TG correlates negatively to HDL-C and this is 
caused by HDL-C effect on TG metabolism.
26-28) Low HDL-C and high 
TG are known to be associated with type 2 diabetes and this is re-
lated to the Koreans’ high carbohydrate diet and obesity.
29)30) Bersot 
et al.
31) reported that high TG being a risk factor of type 2 diabetes, 
Table 5. Distribution of awareness of this diagnosis, and treatment by TLC or drug therapy with high LDL-C in Korean adults
Variables Total
TLC (high LDL-C)* Drug therapy (very high LDL-C)
†
N Awareness
‡ Treatment
§ N Awareness
‡ Treatment
§
Total 4934 984 78 (7.9) 21 (2.1) 664 54 (8.1) 18 (2.7)
Age (years)
20-29 632 23 0 (0.0) 0 (0.0) 5 0 (0.0) 0 (0.0)
30-39 1165 82 3 (3.7) 0 (0.0) 27 1 (3.7) 0 (0.0)
40-49 1244 198 16 (8.1) 1 (0.5) 132 8 (6.1) 1 (0.8)
50-59 814 249 21 (8.4) 4 (1.6) 164 14 (8.5) 4 (2.4)
60-69 712 272 31 (11.4) 14 (5.1) 202 26 (12.9) 11 (5.4)
70-79 367 160 7 (4.4) 2 (1.3) 134 5 (3.7) 2 (1.5)
Sex
Male 2048 490 36 (7.3) 6 (1.2) 391 28 (7.2) 6 (1.5)
Female 2886 494 42 (8.5) 15 (3.0) 273 26 (9.5) 12 (4.4)
ATP III risk category
CHD risk equivalent
  (10 year risk >20%)
483 359 27 (7.5) 12 (3.3) 359 27 (7.5) 12 (3.3)
2+ risk factors
  (10 year risk ≤20%)
1454 451 42 (9.3) 9 (2.0) 275 26 (9.5) 6 (2.2)
0-1 risk factors 2997 174 9 (5.2) 0 (0.0) 30 1 (3.3) 0 (0.0) 
Values for awareness and treatment are n (%). *High LDL-C was defined patients for initiate therapeutic lifestyle change by NCEP ATP III, 
†Patients for drug 
therapy by NCEP ATP III, 
‡Self-report of any prior diagnosis of dyslipidemia by a health-care professional, 
§Self-report current use of cholesterol lowering 
medication. LDL-C: low density lipoprotein-cholesterol, TLC: therapeutic lifestyle changes, CHD: coronary heart disease, NCEP ATP III: National Cholesterol 
Education Program Adult Treatment Panel III93 Sun-Ja Choi, et al.
http://dx.doi.org/10.4070/kcj.2012.42.2.86 www.e-kcj.org
acute pancreatitis as well as increased risk of CVD by two-fold. Thus 
overall ma  nagement or control of dyslipidemia including high TG 
as well as high LDL-C and low HDL-C is thought to be crucial. 
In the present study, the awareness and treatment rates of high 
LDL-C group in need of drug therapy was very low, at 8.1% and 
2.7% respectively, and this study demonstrated significant differ-
ence between the awareness and treatment rates of hypertension 
in Korean. According to in-depth analysis of KNHANES in 2005, the 
hyper  tension awareness and treatment rate in adults over 20 years 
of age has increased respectively from 24.2% to 58.7% and from 
17.0% to 45.7% between 1998 and 2005.
5) Also, the political ap-
proaches to increase the awareness and treatment rates of high 
LDL-C level were insuf  ficient compared to that of hypertension. 
Since 1960, adherence to federal and state policies to lower TC 
and LDL-C level resulted in continuous de  crease of LDL-C level in the 
United States, which result  ed in decrease of death from CVD. How-
ever, Korea lacks the data to establish dyslipidemia guidelines. Cur-
rently, the health insurance system covers reimbursement when a 
patient meets the treatment criteria for dyslipi  demia: TC over 250 
mg/dL for the prevention of CVD, or TC over 220 mg/dL when risk 
factors such as IHD history, hypertension, and diabetes are present.
32) 
Recent  ly, LDL-C level is advised to be less than 100 mg/dL, but sub-
jects with high risk may not be treated when the TC level is less than 
220 mg/dL. Therefore, we need a change in policies based on evid-
ence, in addition to con  tinuing efforts to increase the low awareness 
and treat  ment rates with active education and regular health ch-
eck-ups. 
This study has several limitations. First, this study failed to provide 
awareness and treatment rate of high LDL-C level in patients with 
existing CHD because this study was only conducted for those with-
out history of CHD. Since KNHANES uses the self-administered qu-
estion  naire to identify the CVD, it was hard to distinguish IHD from 
other heart diseases. Therefore, our study was proposed to provide 
guideline for primary prevention measures to those without history 
of CHD. Second, fa  milial history of CHD (development or death from 
CHD of parents or siblings before age of 55) among major CHD risk 
factors by the NCEP ATP III guideline was not investigated. Health 
examination survey does not include CHD family history with the 
age of onset, there  fore family history with CHD was excluded from 
the Framingham score analysis. Third, LDL-C level was cal  culated by 
the method of Friedewald formula,
20) therefore this seem to be in-
sufficiency to reflect the exact concentration. 
In conclusion, 19.9% was in need of TLC and 13.5% was in need 
of drug therapy among Korean subjects with  out CHD according to 
NCEP ATP III guideline. The prevalence of high LDL-C was the highest 
in the group with risks equivalent to CHD. Only 8.1% of the high 
LDL-C group in need of drug therapy was aware of dys  lipidemia and 
2.7% of these subjects were on drug th  erapy, which indicate low 
awareness and treatment rates in our population. Continuous ef-
forts are therefore need  ed to decrease the LDL-C levels in the high 
risk groups to prevent CVD. 
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